AGAyumi Gomyo

Ayumi Gomyo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayumi Gomyo has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Repertoire diversity and dynamics of peripheral Th17 after allogeneic haematopoietic stem cell transplantation

    by Masaharu Tamaki, Hideki Nakasone, Shunto Kawamura, Kosuke Takano, Yukiko Misaki, Kazuki Yoshimura, Yosuke Okada, Aki Tanihara, Koki Hashino, Kaisuke Yamamoto, et al.

    Summary: Th17, a subset of helper T cells that produce interleukin‐17 (IL‐17), is thought to play a pivotal role in the pathogenesis of chronic graft‐versus‐host disease (GVHD). However, the kinetics of Th17 following allogeneic haematopoietic stem cell transplantation (allo‐HSCT) have not been elucidated. In this study, we evaluated the temporal dynamics and diversity of peripherally circulating Th17 after allo‐HSCT. The study included 86 patients who survived without disease relapse for 1 year or more, and for whom peripheral blood samples 3 months after allo‐HSCT were available. Th17 was detected and sorted by flow cytometry, and T‐cell receptor (TCR) repertoire was analysed by a next‐generation sequencing (NGS) method. Patients with chronic GVHD showed a higher TCR repertoire diversity, while those with severe chronic GVHD showed a lower TCR diversity and Th17/Cluster of Differentiation (CD) 4 ratio. The amino acid sequence in complementarity determining region 3 of Th17‐TCR was not apparently different between patients with and without chronic GVHD. Additionally, a higher Th17/CD4 ratio at 3 months was related to a lower incidence of subsequent chronic GVHD. The current study explored the kinetics of peripherally circulating Th17 after allo‐HSCT, which might be associated with the development of chronic GVHD.

  • A Novel Indicator of Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation: Current CMV Reactivation

    by Shunto Kawamura, Hideki Nakasone, Yuki Honjo, Junko Takeshita, Yukiko Misaki, Kosuke Takano, Kazuki Yoshimura, Koki Hashino, Kaisuke Yamamoto, Yuya Nakata, et al.

    Background: Cytomegalovirus reactivation (CMVR) after allogeneic hematopoietic cell transplantation (allo‐HCT) is a reversible event, and conventional indicators such as the simple cumulative incidence cannot reflect transitional CMVR states. We propose a novel indicator, current CMVR (cCMVR), which visualizes both the occurrence and remission of CMVR over time. Methods: To evaluate the utility of cCMVR, we analyzed 389 CMV seropositive patients who had received their first allo‐HCT. cCMVR was defined as the probability of the state where anti‐CMV drugs were administered for CMVR or CMV disease without relapse or death at any time. Results: We compared two groups with or without letermovir prophylaxis (LTV and no‐LTV groups). The 1‐, 2‐, 3‐, and 6‐month cCMVR values were 0.0%, 0.0%, 2.9%, and 2.9% in the LTV group, and 7.1%, 31.9%, 11.0%, and 0.8% in the no‐LTV group. In the LTV group, cCMVR never exceeded 10%, while in the no‐LTV group, cCMVR peaked at approximately 2 months after allo‐HCT, and fewer than 5% of patients developed CMVR after 4 months post‐HCT. Next, in the no‐LTV group, we assessed cCMVR stratified according to the presence of risk factors for the simple cumulative incidence of CMVR, and this revealed that patients grafted from HLA‐mismatched related donors and those who received alemtuzumab for GVHD prophylaxis appeared to experience repeated episodes of CMVR, whereas the early difference in cCMVR according to pretransplant CMV‐IgG titer diminished over time. Conclusion: cCMVR could be a valuable indicator for visualizing recurrent CMV infection and illustrating differences in the time course of CMVR.

  • Serum thioredoxin at allogeneic haematopoietic stem cell transplantation predicts acute graft‐versus‐host disease

    by Masaharu Tamaki, Hideki Nakasone, Kosuke Takano, Shunto Kawamura, Yukiko Misaki, Kazuki Yoshimura, Yosuke Okada, Aki Tanihara, Koki Hashino, Kaisuke Yamamoto, et al.

    Summary: Thioredoxin (TXN) is a component of a major reductive system in various eukaryotes. Although oxidative stress is considered to contribute to the development of acute graft‐versus‐host disease (GVHD), the clinical significance of TXN remains to be elucidated. The current study included 118 patients who had undergone their first allogeneic haematopoietic stem cell transplantation (allo‐HSCT) between 2022 and 2025, and their serum samples at day 0 were sequentially collected (training cohort). The study also assessed 47 patients who had undergone their first allo‐HSCT between 2012 and 2015 and whose serum at around day 0 had previously been cryopreserved and was available (validation cohort). The high‐TXN group showed a lower cumulative incidence of grade II–IV acute GVHD (100‐day incidence: 47.5% vs. 59.2%), although the difference did not reach statistical significance ( p = 0.058). The validation cohort demonstrated similar results (0% vs. 35.8%, p = 0.053). However, multivariate analysis revealed that high‐TXN group was significantly associated with a reduced risk of acute GVHD (hazard ratio [HR] 0.48, p = 0.031). In addition, the combination of TXN with clinical factors enhanced the predictive potential for acute GVHD compared with that of clinical factors alone ( p = 0.0039). TXN might be useful for predicting acute GVHD and could contribute to the establishment of a prediction model.

  • Open Access

    Clinical Impact of Pretransplantation Physical Function on Transplantation after Allogeneic Hematopoietic Cell Transplantation in Older Adults

    by Ayumi Gomyo, Shun-Ichi Kimura, Junko Suzuki, Takuto Ishikawa, Tomohiro Meno, Akari Matsuoka, Yuhei Nakamura, Masakatsu Kawamura, Shunto Kawamura, Junko Takeshita, et al.

  • Prospective validation of the L-index reflecting both the intensity and duration of lymphopenia and its detailed evaluation using a lymphocyte subset analysis after allogeneic hematopoietic stem cell transplantation

    by Shun-Ichi Kimura, Miki Sato, Yukiko Misaki, Kazuki Yoshimura, Ayumi Gomyo, Jin Hayakawa, Yu Akahoshi, Naonori Harada, Masaharu Tamaki, Machiko Kusuda, et al.